Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.

MLA

Joo, Victor, et al. “Primary Prophylaxis with MTOR Inhibitor Enhances T Cell Effector Function and Prevents Heart Transplant Rejection during Talimogene Laherparepvec Therapy of Squamous Cell Carcinoma.” Nature Communications, vol. 15, no. 1, Apr. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1038/s41467-024-47965-3.

APA

Joo, V., Abdelhamid, K., Noto, A., Latifyan, S., Martina, F., Daoudlarian, D., De Micheli, R., Pruijm, M., Peters, S., Hullin, R., Gaide, O., Pantaleo, G., & Obeid, M. (2024). Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. Nature Communications, 15(1), 1–12. https://doi.org/10.1038/s41467-024-47965-3

Chicago

Joo, Victor, Karim Abdelhamid, Alessandra Noto, Sofiya Latifyan, Federica Martina, Douglas Daoudlarian, Rita De Micheli, et al. 2024. “Primary Prophylaxis with MTOR Inhibitor Enhances T Cell Effector Function and Prevents Heart Transplant Rejection during Talimogene Laherparepvec Therapy of Squamous Cell Carcinoma.” Nature Communications 15 (1): 1–12. doi:10.1038/s41467-024-47965-3.